Lewis, K., Ascierto, P., Robert, C., Munhoz, R., Liszkay, G., Marino, L. D. L. C., Olah, J., Queirolo, P., Mackiewicz, J., Shah, K., Forbes, H., Hertig, C., Yan, Y., Gutzmer, R., & McArthur, G. (n.d.). 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study. Journal for immunotherapy of cancer, 8, A188–A189. http://access.bl.uk/ark:/81055/vdc_100144720514.0x000006